Cargando…
Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010–2018 remained proportionally s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853566/ https://www.ncbi.nlm.nih.gov/pubmed/33496238 http://dx.doi.org/10.3201/eid2702.202728 |
_version_ | 1783645988950376448 |
---|---|
author | Schwartz, Amy M. Kugeler, Kiersten J. Nelson, Christina A. Marx, Grace E. Hinckley, Alison F. |
author_facet | Schwartz, Amy M. Kugeler, Kiersten J. Nelson, Christina A. Marx, Grace E. Hinckley, Alison F. |
author_sort | Schwartz, Amy M. |
collection | PubMed |
description | We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010–2018 remained proportionally stable, despite fluctuations in the number of enrollees. Annual incidence of Lyme disease diagnoses per 100,000 enrollees ranged from 49 to 88, ≈6–8 times higher than that observed for cases reported through notifiable disease surveillance. Age and sex distributions among Lyme disease diagnoses in MarketScan were similar to those of cases reported through surveillance, but proportionally more diagnoses occurred outside of peak summer months, among female enrollees, and outside high-incidence states. Misdiagnoses, particularly in low-incidence states, may account for some of the observed epidemiologic differences. Commercial claims provide a stable data source to monitor trends in Lyme disease diagnoses, but certain important characteristics warrant further investigation. |
format | Online Article Text |
id | pubmed-7853566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-78535662021-02-09 Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 Schwartz, Amy M. Kugeler, Kiersten J. Nelson, Christina A. Marx, Grace E. Hinckley, Alison F. Emerg Infect Dis Research We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010–2018 remained proportionally stable, despite fluctuations in the number of enrollees. Annual incidence of Lyme disease diagnoses per 100,000 enrollees ranged from 49 to 88, ≈6–8 times higher than that observed for cases reported through notifiable disease surveillance. Age and sex distributions among Lyme disease diagnoses in MarketScan were similar to those of cases reported through surveillance, but proportionally more diagnoses occurred outside of peak summer months, among female enrollees, and outside high-incidence states. Misdiagnoses, particularly in low-incidence states, may account for some of the observed epidemiologic differences. Commercial claims provide a stable data source to monitor trends in Lyme disease diagnoses, but certain important characteristics warrant further investigation. Centers for Disease Control and Prevention 2021-02 /pmc/articles/PMC7853566/ /pubmed/33496238 http://dx.doi.org/10.3201/eid2702.202728 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Schwartz, Amy M. Kugeler, Kiersten J. Nelson, Christina A. Marx, Grace E. Hinckley, Alison F. Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 |
title | Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 |
title_full | Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 |
title_fullStr | Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 |
title_full_unstemmed | Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 |
title_short | Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 |
title_sort | use of commercial claims data for evaluating trends in lyme disease diagnoses, united states, 2010–2018 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853566/ https://www.ncbi.nlm.nih.gov/pubmed/33496238 http://dx.doi.org/10.3201/eid2702.202728 |
work_keys_str_mv | AT schwartzamym useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018 AT kugelerkierstenj useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018 AT nelsonchristinaa useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018 AT marxgracee useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018 AT hinckleyalisonf useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018 |